Also relating to PDGF-B/PDGFR-β signaling, Lebrin et al. (2010) showed that the drug thalidomide reduced bleeding in patients with hereditary hemorrhagic telangiectasia (HHT), a disease involving vascular malformations and bleeds in multiple organs. This evidence concerns the gene PDGFB and hereditary hemorrhagic telangiectasia.